Email this article LEVELS OF PERIPHERAL BLOOD CYTOKINES AND THE RISK FOR METABOLIC SYNDROME IN PATIENTS WITH STAGE II ESSENTIAL HYPERTENSION
- Authors: Radaeva O.A.1, Simbirtsev A.S.2
-
Affiliations:
- National Research Mordovia State University1
- State Research Institute of Highly Pure Biopreparations, FMBA
- Issue: Vol 22, No 2-2 (2019)
- Pages: 900-902
- Section: ORIGINAL ARTICLES
- Submitted: 28.06.2020
- Accepted: 28.06.2020
- Published: 15.07.2019
- URL: https://rusimmun.ru/jour/article/view/387
- DOI: https://doi.org/10.31857/S102872210006549-8
- ID: 387
Cite item
Full Text
Abstract
The aim of this study was to investigate a correlation between the levels of IL-1β, IL-1α, IL-1ra, IL-18, IL-18BP, IL-37, IL-6, sIL-6r, LIF, sLIFr, IGF-1, IGFBP-1, TNF-α/sTNF-RI, sVCAM-1, IL-17, IL-2, IL-4, IL-10, TGF-β1, IL-8, CX3CL1, CXCL10, INFγ, M-CSF, IL-34, VEGF-A, ЕРО in the peripheral blood of patients with stage II EH and the rate of metabolic syndrome (MS) occurring in a 5-year follow-up period. Twenty-eight cytokines were measured using ELISA in the peripheral blood samples of 200 patients with stage II EH. The patients were followed up for 5 years to keep track of MS. The multivariate Cox regression analysis was applied to the following parameters: IL-1β>20,3 pg/ ml; LIF > 9,13 пг/мл; M-CSF>4538 pg/ml; IGF-1<116000 pg/ml. The analysis revealed that M-CSF> 453 pg/ml (р < 0.001) and IGF-1<116000 pg/ml (р < 0.001) correlated with an increase in the risk for MS in stage II EH.
Keywords
About the authors
O. A. Radaeva
National Research Mordovia State University1
Author for correspondence.
Email: radaevamed@mail.ru
PhD, docent of chair of Immunology, Microbiology, Virology,
Saransk
Russian FederationA. S. Simbirtsev
State Research Institute of Highly Pure Biopreparations, FMBA
Email: fake@neicon.ru
Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor,
St. Petersburg
Russian FederationReferences
- Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014; 2(8), 634–647.
- Srikanthan K., Feyh A., Visweshwar H., Shapiro J. I., Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int. J. Med. Sci. 2016; 13(1), 25–38.
- Радаева О. А., Симбирцев А. С. М-CSF, IL-34, VEGF-A как факторы риска развития инфаркта миокарда, острого нарушения мозгового кровообращения у больных эссенциальной артериальной гипертензией. Российский иммунологический журнал. 2015; 9(18). № 1, 93–101.
- Nagareddy P. R., Kraakman M., Masters S. L., Stirzaker R. A., Gorman D. J., Grant R. W., Dragoljevic D., Hong E. S., Abdel-Latif A., Smyth S. S., Choi S. H., Korner J., Bornfeldt K. E., Goldberg I. J., Murphy A. J. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 2014; 19 (5), 821–835.
- Khalyfa A., Kheirandish-Gozal L., Gozal D. Exosome and Macrophage Crosstalk in Sleep-Disordered Breathing-Induced Metabolic Dysfunction. Int. J. Mol. Sci. 2018; 19 (11), 3383–3341.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).